Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the announcement on 12 August 2022 that the Government will not be procuring any doses of Evusheld, and to data in the journal Clinical Infectious Diseases, published on 29 July 2022, which showed that immunocompromised individuals administered with that drug were 92 per cent less likely to be hospitalised or die than those who did not receive it, if he will reconsider the decision not to procure any doses of Evusheld.

The decision not to procure Evusheld at this time for prevention through emergency routes is based on independent clinical advice by the multi-agency RAPID C-19 and a national expert policy working group. The decision is based on a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies. RAPID C-19 monitors activity in clinical trials for emerging evidence and where treatments are proven to be clinically effective, enables access for National Health Service patients. The Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and it should now be referred to the National Institute for Health and Care Excellence for further evaluation. The Antivirals and Therapeutics Taskforce has published this analysis of evidence, which is available at the following link:

https://www.gov.uk/government/publications/rapid-c-19-oversight-group-report-to-chief-medical-officer-review-of-evusheld

A letter was issued to patient groups on 5 September on the evidence and expert analysis for the decision, which is available at the following link:

https://www.gov.uk/government/publications/decision-on-evusheld-as-a-coronavirus-covid-19-treatment-letter-to-patient-groups